Efficacy and safety of botulinum toxin type a (bont-a) use in the treatment of chronic migraine: a systematic review and meta-analysis
Abstract
Background: Chronic Migraine (CM) is a disabling neurological disorder classified as a complication of migraine. Patients with CM experience headaches on 15 or more days per month in at least three consecutive months. Despites the range of therapeutic treatments, in some cases current treatments often have limited efficacy and intolerable adverse events, highlighting gaps in prophylactic treatment options. OnabotulinumtoxinA (BoNT-A), a purified protein that blocks acetylcholine release from presynaptic neurons and inhibits muscle contractions, has shown pain relief in various conditions, including migraine. Clinical trials suggest that BoNT-A may be an effective and safe prophylactic medication for treating migraines and other headache disorders. Objective: To evaluate the efficacy and safety of BT-A in the treatment of chronic migraine through a systematic review and meta-analysis. Methods: The literature search was performed using PubMed, Scopus, and Web of Science databases. The inclusion criteria consisted of randomized controlled trials that evaluated the use of BoNT-A in patients diagnosed with chronic migraine, comparing it to a placebo group. Studies were screened and selected based on relevance, and data were extracted by independent reviewers. The primary outcomes were the reduction in the number of headache days and the incidence of adverse events. All statistical analyses were performed using the RStudio (version 4.3.2). Results: A total of 11 studies and 3.617…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 617 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.